Home >  News >  Industry >  Pharma News >  Cough syrup deaths: DCGI...

Cough syrup deaths: DCGI directs drug manufacturers not to use propylene glycol supplied by Delhi firm

Uzbekistan alleged in December last year that several children died after consuming Marion Biotech's cough syrups, which it claimed were contaminated with unacceptable amounts of ethylene glycol or propylene glycol.;

By - Ruchika Sharma
Published On 2023-03-11 08:30 GMT   |   Update On 2023-03-11 08:30 GMT
Advertisement

New Delhi: India's drug regulator has directed drug manufacturers not to use propylene glycol supplied by a Delhi-based company which provided the ingredient to Marion Biotech, whose cough syrups were alleged to have led to the deaths of children in Uzbekistan. Maya Chemtech India Pvt. Ltd. supplied propylene glycol used in Marion Biotech's cough syrups that were found to be "not of standard quality", according to the regulator.

Three employees of Marion Biotech were arrested on charges of manufacture and sale of adulterated drugs.
Also, the drugs inspector from the Central Drugs Standard Control Organisation (CDSCO) North Zone last week issued a notice to the pharmaceutical firm asking it to stop the sale and distribution of the drug concerned, stating that the sample was found to be "not of standard quality".
Advertisement
Uzbekistan alleged in December last year that several children died after consuming Marion Biotech's cough syrups, which it claimed were contaminated with unacceptable amounts of ethylene glycol or propylene glycol.
According to a communication sent by Drug Controller General of India (DCGI) Rajeev Raghuvanshi to the licensing authorities of all states and Union territories on March 7, during the course of investigation a total of 33 samples were drawn by drugs inspectors. The test reports of 30 drug samples have been received, wherein 24 samples were declared as "not of standard quality".
Also, out of these samples, 22 fall under the category of adulterated/spurious under Sections 17A and 178 of the Drugs and Cosmetics Act, 1940.
"It is further informed that M/s Maya Chemtech India Pvt. Ltd...was mainly the supplier of propylene glycol which has been used in the impugned batches. In view of the above, you are requested to issue directions to all manufacturers in your jurisdiction not to use propylene glycol supplied by Maya Chemtech India Pvt," the DCGI said in the letter.
Accordingly, he also requested them to instruct their enforcement officials to keep strict vigil on the matter and take stringent action as per law against the offenders in public interest.
On January 12, the World Health Organization (WHO) had issued a "medical product alert", referring to two substandard (contaminated) products, identified in Uzbekistan and reported to it on December 22, 2022.
"The two products are AMBRONOL syrup and DOK-1 Max syrup. The stated manufacturer of both products is MARION BIOTECH PVT. LTD, (Uttar Pradesh, India). To date, the stated manufacturer has not provided guarantees to WHO on the safety and quality of these products," the WHO had said then.
"Laboratory analysis of samples of both products, undertaken by national quality control laboratories of the Ministry of Health of the Republic of Uzbekistan found both products contained unacceptable amounts of diethylene glycol and/or ethylene glycol as contaminants," it had noted
Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Sanofi earns orphan drug designation from USFDA for multiple myeloma drug

Govt sets target to open 25000 Jan Aushadhi Kendras by March 2027: Minister

AbbVie seeks USFDA nod for combination regimen of Venclexta, Acalabrutinib for previously untreated patients with Chronic Lymphocytic Leukemia

NPPA Approves Separate Price for GSK's New Paracetamol-Phenylephrine Sachet

Torrent Pharma Gears Up to Launch Oral, Injectable Semaglutide in 2026 Post Patent Expiry: Report

Intas Pharma appoints Umesh Gupta as Associate Executive Vice President - Manufacturing Operations

Raid in Paschim Vihar: Counterfeit medicine racket busted

Syngene International appoints Gaurav Kushwaha as new Chief Technology Officer